Rafael Holdings investor deck: Phase 3 primary endpoint missed; cash $22.1 million
Rafael Holdings furnished an November 2026 investor presentation under Regulation FD, posted on its website from November 9, 2026. The deck restates that the pivotal Phase 3 TransportNPC study for remibetadex missed its primary endpoint, with a 64% slowing of disease progression versus placebo that was not statistically significant (p=0.19), and that a New Drug Application was submitted in October 2026. The filing also cites substantial doubt about the company's ability to continue as a going concern and its need for additional capital.
Key points
- Primary endpoint: 64% slowing of disease progression versus placebo, difference −0.81 (p=0.19), described as not statistically significant; a prespecified subgroup analysis reached p=0.046.
- Serious treatment-emergent adverse events: 35.9% of remibetadex participants versus 16.7% on placebo over 96 weeks.
- NDA submitted October 2026; Day 60 FDA filing decision expected December 27, 2026; potential FDA action around mid-2027 if priority review is granted.
- Cash balance of $22.1 million as of July 31, 2026; the forward-looking statements cite going concern doubt and need for additional capital.
The filing
Written by AI on Nov 9, 2026, 4:46 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.